aricept - search results

Australia - English - Department of Health (Therapeutic Goods Administration)

aricept donepezil hydrochloride 10mg tablet blister pack

pfizer australia pty ltd - donepezil hydrochloride, quantity: 10 mg (equivalent: donepezil, qty 9.12 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; maize starch; lactose monohydrate; hyprolose; titanium dioxide; macrogol 8000; hypromellose; iron oxide yellow; purified talc - aricept (donepezil hydrochloride) is indicated for the treatment of mild, moderate and severe alzheimer's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

aricept donepezil hydrochloride 5mg tablet blister pack

pfizer australia pty ltd - donepezil hydrochloride, quantity: 5 mg (equivalent: donepezil, qty 4.56 mg) - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; hyprolose; magnesium stearate; microcrystalline cellulose; titanium dioxide; macrogol 8000; hypromellose; purified talc - aricept (donepezil hydrochloride) is indicated for the treatment of mild, moderate and severe alzheimer's disease.

United States - English - NLM (National Library of Medicine)

aricept- donepezil hydrochloride tablet, film coated aricept odt- donepezil hydrochloride tablet, orally disintegrating

eisai inc. - donepezil hydrochloride (unii: 3o2t2pj89d) (donepezil - unii:8ssc91326p) - donepezil hydrochloride 5 mg - aricept is indicated for the treatment of dementia of the alzheimer’s type. efficacy has been demonstrated in patients with mild, moderate, and severe alzheimer’s disease. aricept is contraindicated in patients with known hypersensitivity to donepezil hydrochloride or to piperidine derivatives. risk summary there are no adequate data on the developmental risks associated with the use of aricept in pregnant women. in animal studies, developmental toxicity was not observed when donepezil was administered to pregnant rats and rabbits during organogenesis, but administration to rats during the latter part of pregnancy and throughout lactation resulted in increased stillbirths and decreased offspring survival at clinically relevant doses [see data ]. in the u.s. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively. the background risks of major birth defects and miscarriage for the indicated popula